vendredi 23 juin 2017

Onco Actu du 23 juin 2017


1. Biologie

The presence of the protein KIF1Bβ can play a central role for the outcome of a neuroblastoma diagnosis [Karolinska Institutet]

Grappling with cancers that break all the rules [STAT]

2.5 Etiologie - Gènes

Everything is genetic, isn't it? [The Mermaid's Tale]

4.7 Dép., diag. & prono. - Col de l'utérus

New ethical lapses alleged in controversial India cervical cancer screening trial [STAT]

4.9 Dép., diag. & prono. - Sein

OB-GYNs Give Women More Say In When They Have Mammograms [NPR]

U.S. physicians move to more flexible mammogram schedule [Reuters]

5.12 Immunothérapies

Was Bristol-Myers Squibb’s assay to blame for Opdivo’s first-line lung flop? [FiercePharma]

5.12.3 Immunothérapies-combinaisons

News Feature: Radiation redux [PNAS]

5.2.3 Pharma - économie

Versant carefully sets the stage for a $68M debut of a biotech player focused on synthetic lethality [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

Rare cancers through the looking glass [Pharmafile]

5.3.4 Traitements - AMM (FDA, EMA)

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 June 2017 [EMA]

Novartis combination targeted therapy Tafinlar® + Mekinist® receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC) [Novartis]

FDA Approves Rituxan Hycela (Rituximab and Hyaluronidase Human) for Subcutaneous Injection in Certain Blood Cancers [Genentech]

FDA grants regular approval to dabrafenib and trametinib combination for metastatic NSCLC with BRAF V600E mutation [FDA]

FDA Grants Regular Approval to Dabrafenib and Trametinib Combination for Metastatic NSCLC with BRAF V600E Mutation [ESMO]

European regulators greenlight U.S. biotech's kidney cancer drug [Reuters]

Novartis breast cancer drug Kisqali wins European panel backing [Reuters]

FDA approves more convenient form of Roche blood cancer drug [Reuters]

5.9.3 EHA

Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL [Novartis]

Novartis data shows half of eligible Ph+ CML-CP patients remain in Treatment-free Remission nearly two years after stopping Tasigna® [Novartis]

AbbVie Announces Pivotal Phase 2 Trial Evaluating VENCLYXTO™ (venetoclax) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) with 17p Deletion to be Presented at 22nd European Hematology Association (EHA) Annual Congress [AbbVie]

6.10.1 Politiques (USA)

ASCO Opposes Senate Healthcare Bill, Urges Lawmakers to Reject Measure [ASCO]

6.6 Publications

US court grants Elsevier millions in damages from Sci-Hub [Nature]

6.8 Communication

Report calls for action to prevent confusion over medicines [European Pharmaceutical Review]

6.9 Controverses

Chinese courts call for death penalty for researchers who commit fraud [STAT]